Zacks Investment Research cut shares of Innovus Pharmaceuticals Inc (NASDAQ:INNV) from a buy rating to a hold rating in a research note issued to investors on Monday.

According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “

Innovus Pharmaceuticals (NASDAQ:INNV) opened at 0.2675 on Monday. The stock’s market capitalization is $23.32 million. Innovus Pharmaceuticals has a 52-week low of $0.03 and a 52-week high of $0.66. The stock has a 50 day moving average of $0.29 and a 200 day moving average of $0.26.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.

5 Day Chart for NASDAQ:INNV

Receive News & Stock Ratings for Innovus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.